N/A N=989 SPECS: Safe Pediatric Euglycemia in Cardiac Surgery
Heart Defects, Congenital · Hyperglycemia
Primary: Incidence of Nosocomial Infections in the Cardiac ICU — 8.6; 9.9 infections / 1000 pt days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=27 Strict Glycemic Control by Insulin Infusion:Observations on Emergency Department Initiation
Hyperglycemia
Primary: Time to Achieve Glycemic Control — 225 Minutes
N/A N=30 Glycemic Optimization On Discharge From the Emergency Room
Diabetes Mellitus
Primary: Change in Diabetes Distress — 0; 0.5 units on a scale
N/A N=101 The Synergy to Control Emergency Department Hyperglycemia Program for Type 2 Diabetes
Diabetes Mellitus, Type 2 · Medication Adherence · HYPERGLYCEMIA
Primary: Hemoglobin A1C at 4 Weeks — 10.5; 11.1 percentage of glycosylated hemoglobin
Phase 4 N=74 Continuous Glucose Sensor Profiles in Non-Diabetic Subjects
Healthy Subjects Without Type 1 Diabetes
Primary: Overall Mean Sensor Glucose by Age Group — 98; 103; 97; 96 mg/dL — p=0.009
Phase 4 N=23 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
Non-Insulin-Dependent Diabetes Mellitus
Primary: Duration of Hyperglycaemia (>126 mg/dL) in Hours at Baseline Compared to After 12 Weeks on Treatment — 17.31; 17.53; 15.30; 10.83 Hours — p=0.064
N/A N=85 Continuous Glucose Monitoring for Hyperglycemia in Critically Ill Patients
Hyperglycemia · Hypoglycemia · Critical Illness
Primary: Time in Target Blood Glucose Range (BG 70-180mg/dL) — 60.5; 61.4 percentage of time within target range
Phase 2 N=74 Intensive Glycemic Control for Congestive Heart Failure Exacerbation
Congestive Heart Failure · Diabetes Mellitus
Primary: Hospital Length of Stay — 7; 8 days
Early Phase 1 N=15 Effect of Hyperglycemia on Microvascular Perfusion in Healthy Adults
Vascular Stiffness · Insulin Sensitivity
Primary: Change in Flow Mediated Dilation (FMD) Between Baseline and After 2 Hour Insulin Clamp — 11.8; 11.8; 8.9; 8.95 % change
N/A N=86 Euglycemia After Antenatal Late Preterm Steroids, the E-ALPS Study
Pregnancy Preterm · Neonatal Hypoglycemia · Hyperglycemia Drug Induced
Primary: Umbilical Cord Blood C-peptide — 1.02; 1.09 ng/mL — p=0.97
Phase 2 N=74 Glycemic Control and Variability for Congestive Heart Failure Exacerbation
Congestive Heart Failure · Diabetes Mellitus
Primary: Hospital Length of Stay — 7; 8 days
N/A N=86 Stop Emergency Room Visits for Hyperglycemia Project - District of Columbia (DC)
Type 2 Diabetes Mellitus
Primary: Total Number of Hypoglycemia Events (Blood Glucose < 60mg/dL) Within 24 Hours of Baseline Visit — 0 events
Phase 3 N=2,684 Computerized Glucose Control in Critically Ill Patients
Hyperglycemia · Critical Illness
Primary: All-cause 90-day Mortality — 431; 447 participants
N/A N=1,439 Outcomes Study of Hyperinsulinemic Glucose Control in Cardiac Surgery
Cardiac Surgery
Primary: Any Major Morbidity/30-day Mortality — 46; 82 Participants — p=0.0043
N/A N=34 Effect of Dialysis Glucose Bath on Glycemic Control in Hemodialysis (HD)
Diabetes Type 2
Primary: Hemoglobin A1c Levels — 7.1; 7.1 percent — p=0.67
Phase 2 N=44 Albiglutide Glucose Clamp Study in Subjects With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Glucagon Concentration (Nanomoles Per Liter [Nmol/L]) During the Hypoglycemic Periods of the Glucose Clamp Procedure — 0.03780; 0.03805; 0.03780; 0.03780 Nanomoles per…
N/A N=13 Effect of Closed Loop Glucose Control on Exercise-Associated Hypoglycemia
Type 1 Diabetes Mellitus
Primary: Plasma Glucose (PG) Response to Exercise — 75; 90.5 mg/dL — p=0.791
Phase 4 N=28 Sitagliptin and Glucagon Counterregulation
Type 2 Diabetes
Primary: Glucagon Counterregulation to Hypoglycemia — 16.0; 16.5 pmol/l
Phase 4 N=15 Effect of Ethanol Intoxication on the Anti-Hypoglycemic Action of Glucagon
Type 1 Diabetes Mellitus
Primary: AOCGIR (Area Over the Curve for Glucose Infusion Rate) — 1996; 1981 mg*minute/dl
N/A N=19 Maximising Time With a Normal Blood Glucose to Restore the Glucagon Response in Type 1 Diabetes
Type 1 Diabetes · Type 1 Diabetes Mellitus With Hypoglycemia · Hypoglycemia
Primary: The Change in Plasma Glucagon Levels (Pmol/L) Measured During Normoglycaemic and Hypoglycaemia — 1.34; 1.68; 2.26; 0.31 pmol/L — p=>0.99
N/A N=2 Closed Loop Glucose Control in Patients With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Percent of All Glucose Values Within Glucose Range < 70 mg/dL — 0 Percentage of all glucose values
N/A N=35 Insulin Sensitivity, Impaired Counterregulation, and Glucose Variability
Type 1 Diabetes Mellitus
Primary: Insulin Sensitivity — 3.37*10^-4 1/min per uU/mL
N/A N=130 Evaluation of an Algorithm for Intensive s.c. Insulin Therapy in Emergency Room Patients With Hyperglycaemia
Hyperglycemias
Primary: Time in the Glycaemic Target Range (5.5-7.0 mmol/l) During the Period of Observation of 48 Hours — 13.0; 22.5 hours
N/A N=4 Use of a Hyperinsulinemic-hypyglycemic Clamp to Study Hypoglycemia: a Method Development Study
Diabetes
Primary: Peak Epinephrine Levels — 609 pg/mL
Phase 4 N=164 Study of Glycemic Control on Liver Transplantation Outcomes
Evidence of Liver Transplantation · Hyperglycemia · Rejection
Primary: Rejection of Liver Transplant — 17; 20 participants — p=0.709
Phase 2 N=30 Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of G-Pen(TM) (Glucagon Injection) to Treat Severe Hypoglycemia
Hypoglycemia
Primary: Serious Adverse Events — 0; 0; 0 events
N/A N=3 Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management
Chronic Kidney Diseases · Type 2 Diabetes
Primary: Glucose Time in Range — 495.2; 573.3 minutes per day
N/A N=7 Closed Loop Glucose Control in Patients With Type 1 and Type 2 Diabetes
Diabetes Mellitus, Type 1 · Diabetes Mellitus, Type 2
Primary: Primary Safety Outcome — 1.4 Percentage of all glucose values
Phase 3 N=81 G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes
Insulin Hypoglycemia · Type 1 Diabetes Mellitus · Severe Hypoglycemia
Primary: Number of Subjects With a Positive Glucose Response — 76; 78 Participants
Phase 3 N=12 The Effect of the Interaction of Glucagon and Insulin on Endogenous Glucose Production in Humans
Healthy
Primary: Endogenous Glucose Production (EGP) — 4.99; 5.02; 6.82; 5.52 umol/kg/min